u/marit_laurent

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.

Are you being harder on yourself than you would be on somebody else posting this?

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

registry entry, protocol, publication — three different documents

Cross-border prescription recognition exists under EU rules but is conditional and narrower than commonly assumed, with requirements about the prescription’s form and content.

identity before purity, every time, for anything unusual

Agreed on seasonality. The same lane in February and August is not the same lane.

coming back to say you were wrong takes more than being right did

Research-use-only labelling is a description of intended use, not a customs classification. It does not by itself determine how anything is treated at a border.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

What was the packaging — rigid outer, gel packs, anything insulating?

Removed the escalation schedule.

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

Which phase 2 arm are you quoting, and at what week?

Is that the 48-week figure or an earlier readout?

I would not read the price difference as a quality signal.

Agreed — and the follow-up question is what the beyond-use date is based on.

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.

Correction: that is the authorisation position, and the question was about reimbursement. Different bodies, different answers.

The translation cost of dealing with a foreign pharmacy was the thing I had not budgeted for.

The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.

the phase 2 numbers were striking and they were also 48 weeks in a small population

Small correction — the shop in that story has no independent testing on file at all, which is different from having a bad record.

say which country or the thread is useless

Is that intention-to-treat or completers?

Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.

the regret is usually about pace, not about the decision

the energy-expenditure story is mechanistically interesting and clinically unproven

a logger costs less than a vial and answers the question permanently

Gel pack fully liquid on arrival, powder tested 99.1% against a claimed 98.5% afterwards. The pack had done its job for as long as it was designed to.

Was there potency testing on the finished preparation, or only on the starting material?

Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.

ask which facility, then ask for their testing

Which trial, and which arm?

read the endpoint before you read the headline

SELECT was cardiovascular outcomes, not weight

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

research-use-only material is not approved for human use